SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Cancer och onkologi) srt2:(2000-2004);srt2:(2003)"

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Cancer och onkologi) > (2000-2004) > (2003)

  • Resultat 1-10 av 232
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Guerin, S, et al. (författare)
  • Radiation dose as a risk factor for malignant melanoma following childhood cancer
  • 2003
  • Ingår i: European Journal of Cancer. - 1879-0852. ; 39:16, s. 2379-2386
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to determine therapy-related risk factors for the development of melanoma after childhood cancer. Among 4401 3-year survivors of a childhood cancer in eight French and British centres and 25 120 patients younger than 20 years old at first malignant neoplasm (FMN) extracted from the Nordic Cancer Registries, 16 patients developed a melanoma as a second malignant neoplasm (SMN). A cohort study of the French and British cohorts was performed. In a nested case-control study, the 16 patients who developed a melanoma as a SMN (cases) were matched with 3-5 controls in their respective cohort according to gender, age at the first cancer, the calendar year of occurrence of the first cancer and follow-up. Radiotherapy appeared to increase the risk of melanoma for local doses > 15 Gy, Odds Ratio (OR)= 13 (95% Confidence Interval (CI): 0.94-174). Regarding chemotherapy, we observed an increased OR for both alkylating agents and spindle inhibitors, OR 2.7 (95% CI: 0.5-14). Children treated for a gonadal tumour as a FMN were found to be at a higher risk of melanoma, OR 8.7 (95% CI: 0.9-86). The adjusted OR for the local radiation dose was 1.07 (95% CI: 1.00-1.15). In conclusion, radiotherapy may contribute to an increased risk of melanoma as a SMN, but only at very high doses of low linear energy transfer radiation. Common genetic origins between gonadal tumours and malignant melanomas are likely. (C) 2003 Elsevier Ltd. All rights reserved.
  •  
4.
  • Smeland, S, et al. (författare)
  • Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders
  • 2003
  • Ingår i: European Journal of Cancer. - 1879-0852. ; 39:4, s. 488-494
  • Tidskriftsartikel (refereegranskat)abstract
    • From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume < 190 ml, 24-h serum methotrexate > 4.5 muM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in > 70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome. (C) 2003 Elsevier Science Ltd. All rights reserved.
  •  
5.
  • Johansson, Bengt, 1958-, et al. (författare)
  • Phantom study of radiation doses outside the target volume brachytherapy versus external radiotherapy of early breast cancer
  • 2003
  • Ingår i: Radiotherapy and Oncology. - Amsterdam : Elsevier. - 1879-0887 .- 0167-8140. ; 69:1, s. 107-112
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and purpose: Brachytherapy is sometimes suggested as an adjuvant treatment after surgery of some tumours. When introducing this, it would be useful to have an estimate of the dose distribution to different body sites, both near and distant to target, comparing conventional external irradiation to brachytherapy. The aim of the present study was to determine radiation doses with both methods at different body sites, near and distant to target, in an experimental situation on an operated left sided breast cancer on a female Alderson phantom. Methods: Five external beam treatments with isocentric tangential fields were given by a linear accelerator. A specified dose of 1.0 Gy was given to the whole left sided breast volume. Five interstitial brachytherapy treatments were given to the upper, lateral quadrant of the left breast by a two plane, 10 needles implant. A dose of 1.0 Gy specified according to the Paris system was administered by a pulsed dose rate afterloading machine. Absorbed dose in different fixed dose points were measured by thermoluminescence dosimeters. Results: Both methods yielded an absorbed dose of the same size to the bone marrow and internal organs distant to target, 1.0-1.4% of the prescribed dose. There was a trend of lower doses to the lower half of the trunk and higher doses to the upper half of the trunk, respectively, by brachytherapy. A 90% reduction of absorbed dose with brachytherapy compared to external irradiation was found in the near-target region within 5 cm from target boundary where parts of the left lung and the heart are situated. If an adjuvant dose of 50 Gy is given with the external radiotherapy and brachytherapy, the absorbed dose in a part of the myocardium could be reduced from 31.8 to 2.1 Gy. Conclusions: Near target, brachytherapy yielded a considerably lower absorbed dose which is of special importance when considering radiation effects on the myocard and lungs. We could not demonstrate any difference of importance, in absorbed dose to dose points distant to target. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
  •  
6.
  • Björnsson, Jon Mar, et al. (författare)
  • Reduced proliferative capacity of hematopoietic stem cells deficient in hoxb3 and hoxb4
  • 2003
  • Ingår i: Blood. - 0006-4971 .- 1528-0020. ; 23:11, s. 3872-3883
  • Tidskriftsartikel (refereegranskat)abstract
    • Several homeobox transcription factors, such as HOXB3 and HOXB4, have been implicated in regulation of hematopoiesis. In support of this, studies show that overexpression of HOXB4 strongly enhances hematopoietic stem cell regeneration. Here we find that mice deficient in both Hoxb3 and Hoxb4 have defects in endogenous hematopoiesis with reduced cellularity in hematopoietic organs and diminished number of hematopoietic progenitors without perturbing lineage commitment. Analysis of embryonic day 14.5 fetal livers revealed a significant reduction in the hematopoietic stem cell pool, suggesting that the reduction in cellularity observed postnatally is due to insufficient expansion during fetal development. Primitive Lin(-) Scal(+) c-kit(+) hematopoietic progenitors lacking Hoxb3 and Hoxb4 displayed impaired proliferative capacity in vitro. Similarly, in vivo repopulating studies of Hoxb3/Hoxb4-deficient hematopoietic cells resulted in lower repopulating capability compared to normal littermates. Since no defects in homing were observed, these results suggest a slower regeneration of mutant HSC. Furthermore, treatment with cytostatic drugs demonstrated slower cell cycle kinetics of hematopoietic stem cells deficient in Hoxb3 and Hoxb4, resulting in increased tolerance to antimitotic drugs. Collectively, these data suggest a direct physiological role of Hoxb4 and Hoxb3 in regulating stem cell regeneration and that these genes are required for maximal proliferative response.
  •  
7.
  • Bondeson, Lennart, et al. (författare)
  • Michelangelo's divine goitre.
  • 2003
  • Ingår i: Journal of the Royal Society of Medicine. - : SAGE Publications. - 0141-0768. ; 96:12, s. 609-611
  • Tidskriftsartikel (refereegranskat)
  •  
8.
  • Hashemi, S H, et al. (författare)
  • 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.
  • 2003
  • Ingår i: The British journal of surgery. - : Oxford University Press (OUP). - 0007-1323 .- 1365-2168. ; 90:5, s. 549-54
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to investigate the importance of somatostatin receptor subtype 2 (SSTR2) expression for 111In-labelled diethylenetriamine-pentaacetic acid (DTPA)-D-Phe1-octreotide binding and uptake of 111In in neuroendocrine tumours.
  •  
9.
  • Kinhult, Sara, et al. (författare)
  • Endothelial damage after treatment with low-molecular weight heparins - a morphological study
  • 2003
  • Ingår i: Scandinavian Cardiovascular Journal. - : Informa UK Limited. - 1651-2006 .- 1401-7431. ; 37:1, s. 30-33
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective-Recent studies failed to show long-term benefit with low-molecular weight heparins (LMWH) in unstable coronary heart disease. A previous study of vascular effects of the cytostatic agent 5-fluorouracil (5-FU) showed that dalteparin prevented thrombosis induced by 5-FU but endothelial damage was not ameliorated and was present also in animals treated with dalteparin only. This study investigates the influence of LMWH currently in clinical use on arterial endothelium in vivo. Design-Eighty rabbits in four groups were treated with dalteparin, enoxaparin, tinzaparin and saline, respectively. Arterial endothelium was examined after 3, 14, 30 and 60 days with scanning electron microscopy. Results-All three groups treated with LMWH showed moderate damage to the endothelium, with contracted vessel wall and endothelial cells, cell membrane damage, denudation of subendothelium and adhering platelets. Contrarily, the control group exhibited a normal endothelium. Conclusion-Morphologic examination of arterial endothelium shows that all investigated LMWH exert a moderate toxic effect on endothelial cells. The clinical impact of these observations, e. g. concerning effect of long-term LMWH treatment, needs to be further elucidated.
  •  
10.
  • Kölby, Lars, 1963, et al. (författare)
  • Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.
  • 2003
  • Ingår i: British journal of cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 89:7, s. 1383-8
  • Tidskriftsartikel (refereegranskat)abstract
    • The radio-iodinated noradrenaline analogue meta-iodobenzylguanidine (MIBG) can be used for scintigraphy and radiation therapy of neuroendocrine (NE). The aim of the present study was to study the importance of vesicular monoamine transporters (VMATs) for the uptake of (123)I-MIBG in NE tumours. In nude mice, bearing the human transplantable midgut carcinoid GOT1, all organs and xenografted tumours accumulated (123)I after i.v. injection of (123)I-MIBG. A high concentration of (123)I was maintained in GOT1 tumours and adrenals, which expressed VMATs, but rapidly decreased in all other tissues. In the VMAT-expressing NE tumour cell lines GOT1 and BON and in VMAT-expressing primary NE tumour cell cultures (carcinoids, n=4 and pheochromocytomas, n=4), reserpine significantly reduced the uptake of (123)I-MIBG. The membrane pump inhibitor clomipramine had no effect on the uptake of (123)I-MIBG in GOT1 and BON cells, but inhibited the uptake in one out of four primary carcinoid cell cultures and three out of four primary pheochromocytoma cell cultures. In conclusion, VMATs and secretory granules are of importance for the uptake and retention of (123)I-MIBG in NE tumours. Information about the type and degree of expression of VMATs in NE tumours may be helpful in future to select patients suitable for radiation therapy with radio-iodinated MIBG.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 232
Typ av publikation
tidskriftsartikel (204)
doktorsavhandling (12)
konferensbidrag (8)
forskningsöversikt (5)
bokkapitel (3)
Typ av innehåll
refereegranskat (215)
övrigt vetenskapligt/konstnärligt (17)
Författare/redaktör
Olsson, Håkan (12)
Fernö, Mårten (11)
Landberg, Göran (9)
Bendahl, Pär Ola (7)
Baldetorp, Bo (7)
Mertens, Fredrik (7)
visa fler...
Mattsson, Sören (7)
Stenram, Unne (6)
Möller, Torgil (6)
Borg, Åke (6)
Anderson, Harald (6)
Svanberg, Sune (5)
Svanberg, Katarina (5)
Strand, Sven-Erik (5)
Påhlman, Sven (5)
Lindholm, C (5)
Hultborn, Ragnar, 19 ... (4)
Larsson, Christer (4)
Berglund, Göran (4)
Sorokin, Lydia (4)
Lennernäs, Bo, 1963 (4)
Pålsson, Sara (4)
Soto Thompson, Marce ... (4)
Glimelius, Bengt (3)
Ringberg, Anita (3)
Andersson-Engels, St ... (3)
Ahlman, Håkan, 1947 (3)
Wängberg, Bo, 1953 (3)
Alm, Per (3)
Tranberg, Karl-Göran (3)
Ringborg, U (3)
Kjellén, Elisabeth (3)
Ljungberg, Michael (3)
Boman, K. (3)
Wallgren, Arne, 1940 (3)
Albertsson, Maria (3)
Ringnér, Markus (3)
Toma-Daşu, Iuliana (3)
Janciauskiene, Sabin ... (3)
Lindegren, Sture, 19 ... (3)
Nilbert, Mef (3)
Gustafson, Pelle (3)
Alvegård, Thor (3)
Rydholm, Anders (3)
Gustavsson, Anita (3)
ZACKRISSON, B (3)
Svensson, H (3)
Jacobsson, Lars, 194 ... (3)
Tennvall, Jan (3)
Loman, Niklas (3)
visa färre...
Lärosäte
Lunds universitet (178)
Karolinska Institutet (33)
Göteborgs universitet (27)
Uppsala universitet (21)
Umeå universitet (14)
Linköpings universitet (12)
visa fler...
Stockholms universitet (5)
Örebro universitet (3)
Södertörns högskola (2)
Kungliga Tekniska Högskolan (1)
Jönköping University (1)
Högskolan i Skövde (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (230)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (232)
Naturvetenskap (4)
År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy